Evidence map›Paper›PMID 39309261›Full record

ArticleMolecular therapy. Methods & clinical development2024

Lentiviral vectors for precise expression to treat X-linked lymphoproliferative disease.

Paul G Ayoub, Julia Gensheimer, Lindsay Lathrop, Colin Juett, Jason Quintos, Kevin Tam, Jack Reid, Feiyang Ma, Curtis Tam, Grace E McAuley and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Paul G AyoubDepartment of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Julia GensheimerDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Lindsay LathropDepartment of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Colin JuettDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jason QuintosDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kevin TamDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jack ReidDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Feiyang MaDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Curtis TamDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Grace E McAuleyDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Devin BrownDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Xiaomeng WuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Ruixue ZhangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kathryn BradfordDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Roger P HollisDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Gay M CrooksDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Donald B KohnDepartment of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Kara W Chew · 2022 to 2026
$15.6M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
UCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Olujimi A Ajijola, David Wayne Dawson · 2024 to 2026
$5.3M
Role of interleukin-6 signaling on T cell potential of aged hematopoietic stem cells and thymic progenitorsF30AG086001 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Julia Gensheimer · 2024 to 2026
$118k
NCI NIH HHS T32 CA009056NIAID NIH HHS P30 AI152501NIA NIH HHS F30 AG086001NIGMS NIH HHS T32 GM007618NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

X-linked lymphoproliferative disease (XLP1) results from

Indexed as

enhancergene therapyHSClentiviral vectorregulatedSAPSH2D1Astem cellXLP

Identifiers

PMID39309261
PMCPMC11415656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.